Claims for Patent: 10,342,764
✉ Email this page to a colleague
Summary for Patent: 10,342,764
Title: | Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same |
Abstract: | Provided herein are methods and compositions for oral administration of therapeutic proteins, improved protease inhibitor preparations, methods for producing same, and compositions comprising same. |
Inventor(s): | Hershko; Avraham (Haifa, IL), Kidron; Miriam (Jerusalem, IL) |
Assignee: | Oramed Ltd. (Jerusalem, IL) |
Application Number: | 14/376,292 |
Patent Claims: | 1. An oral pharmaceutical composition produced by a process comprising (a) subjecting soybean trypsin inhibitor (SBTI) to column chromatography under conditions in
which fractions containing the SBTI's Bowman-Birk Inhibitor (BBI) activity elute separately from fractions containing the SBTI's Kunitz Trypsin Inhibitor (KTI) activity; (b) eluting and combining fractions from (a) that contain the BBI activity; (c)
filtering the combined fractions from (b) that contain the BBI activity under conditions that reduce the contaminants having a molecular weight of greater than 30 KDa to be less than 0.1% of the BBI preparation, thus producing a purified BBI product
characterized in that: (i) contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the preparation; and (ii) 1 mg of the purified BBI product has an activity of about 40 BTEE units per mg of protein; (d) eluting and combining
the fractions from (a) that contain the KTI activity and in which contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the preparation thus producing a purified KTI product characterized in that: (i) contaminants having a
molecular weight greater than 30 KDa are less than 0.1% of the preparation; and (ii) 1 mg of the purified KTI product has an activity of about 10,000 BAEE units per mg of protein; (e) combining (i) an oil-based liquid formulation, (ii) a therapeutic
protein having a molecular weight of up to 100 kilodalton, (iii) a chelator of divalent cations, (iv) the purified BBI product of part (c); and (v) the purified KTI product of part (d), such that the ratio of anti-chymotrypsin activity to anti-trypsin
activity present in the pharmaceutical composition is between 1.5:1 and 1:1 inclusive.
2. The oral pharmaceutical composition of claim 1, wherein said oil-based liquid formulation further comprises a trypsin inhibitor other than said BBI and said KTI. 3. The oral pharmaceutical composition of claim 1, wherein said KTI is Kunitz trypsin inhibitor 3 (KTI3). 4. The oral pharmaceutical composition of claim 3, wherein said KTI3 has been purified to at least 85% purity as measured by SDS-PAGE. 5. The oral pharmaceutical composition of claim 3, wherein said KTI3 has been purified to a protein content of greater than 95% as measured by BCA assay. 6. The oral pharmaceutical composition of claim 1, wherein the oil-based liquid formulation comprises BBI that has an anti-chymotrypsin activity of at least 40 mg chymotrypsin inhibited per ml of the liquid formulation. 7. The oral pharmaceutical composition of claim 6, wherein said oil-based liquid formulation further comprises an anti-trypsin activity of at least 20 mg trypsin inhibited per ml of the liquid formulation. 8. The oral pharmaceutical composition of claim 1, wherein said therapeutic protein is selected from the group consisting of insulin, influenza hemagglutinin, influenza neuraminidase, a glucagon, interferon gamma, interferon beta, interferon alpha, growth hormone, erythropoietin, GLP-1, a GLP-1 analogue, granulocyte colony stimulating factor (G-CSF), renin, growth hormone releasing factor, parathyroid hormone, thyroid stimulating hormone, follicle stimulating hormone, calcitonin, luteinizing hormone, glucagon, a clotting factor, an anti-clotting factor, atrial natriuretic factor, surfactant protein A (SP-A), surfactant protein B (SP-B), surfactant protein C (SP-C), surfactant protein D (SP-D), a plasminogen activator, bombesin, hemopoietic growth factor (colony-stimulating factor, multiple), a tumor necrosis factor (TNF) protein, enkephalinase, RANTES (regulated on activation normally T-cell expressed and secreted), human macrophage inflammatory protein (MIP-1-alpha), serum albumin, Mullerian-inhibiting substance, relaxin, mouse gonadotropin-releasing hormone, DNase, inhibin, activin, vascular endothelial growth factor (VEGF), a neurotrophic factor, neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), nerve growth factor, platelet-derived growth factor (PDGF), a fibroblast growth factor, a transforming growth factor (TGF), insulin-like growth factor-I and -II (IGF-1 and IGF-II), des (1-3)-IGF-1 (brain IGF-1), insulin-like growth factor binding protein 1 (IGFBP-1), IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6, a keratinocyte growth factor, an osteoinductive factor, bone morphogenetic protein (BMP)-2, BMP-7, a colony stimulating factor (CSF), an interleukin (IL), superoxide dismutase, decay accelerating factor, a chemokine family member, and a complement factor. 9. The oral pharmaceutical composition of claim 8, wherein said therapeutic protein is selected from the group consisting of insulin and a GLP-1 analogue. 10. The oral pharmaceutical composition of claim 1, wherein said chelator is EDTA. 11. The oral pharmaceutical composition of claim 1, wherein said oil-based liquid formulation further comprises a polyethylene glycol (PEG) ester of a monoglyceride, a diglyceride, a triglyceride, or a mixture thereof. 12. The oral pharmaceutical composition of claim 11, wherein said oil-based liquid formulation further comprises a free PEG. 13. The oral pharmaceutical composition of claim 11, wherein said PEG ester is provided as a mixture of (a) a monoacylglycerol, a diacylglycerol, a triacylglycerol, or a mixture thereof; and (b) a polyethylene glycol (PEG) ester of a fatty acid. 14. The oral pharmaceutical composition of claim 13, wherein part (a) of said mixture comprises C.sub.8-C.sub.18 monoacylglycerols, diacylglycerols, and triacyl glycerols. 15. The oral pharmaceutical composition of claim 13, wherein part (b) of said mixture comprises PEG monoesters and diesters of a mixture of C.sub.8-C.sub.18 fatty acids. 16. The oral pharmaceutical composition of claim 13, wherein part (a) of said mixture comprises C.sub.8-C.sub.18 monoacylglycerols, diacylglycerols, and triacylglycerols; part (b) of said mixture comprises PEG-32 monoesters and diesters of a mixture of C.sub.8-C.sub.18 fatty acids; said oil-based liquid formulation further comprises (c) free PEG-32; and the weight/weight ratio of part (a) of said mixture to the sum of part (b) of said mixture and (c) is between 10:90 and 30:70 inclusive. 17. The oral pharmaceutical composition of claim 16, wherein (a), (b), and (c) together constitute 8-16% weight/weight inclusive of said oil-based liquid formulation. 18. The oral pharmaceutical composition of claim 11, further comprising a non-ionic detergent. 19. The oral pharmaceutical composition of claim 18, wherein said non-ionic detergent is a polysorbate-based detergent. 20. The oral pharmaceutical composition of claim 19, wherein said polysorbate-based detergent is polysorbate 80. 21. The oral pharmaceutical composition of claim 20, wherein said polysorbate 80 constitutes 3-10% weight/weight inclusive of said oil-based liquid formulation. 22. The oral pharmaceutical composition of claim 1, wherein said oil is a fish oil. 23. The oral pharmaceutical composition of claim 1, wherein said oil-based liquid formulation is water-free. 24. The oral pharmaceutical composition of claim 1, further comprising a coating that resists degradation in the stomach. 25. The oral pharmaceutical composition of claim 24, wherein said coating is a pH-sensitive capsule. 26. The oral pharmaceutical composition of claim 24, wherein said coating is a soft gelatin capsule. 27. The oral pharmaceutical composition of claim 1, wherein the BBI is isolated from a soybean product. 28. The oral pharmaceutical composition of claim 1, wherein the SBTI is recombinant. 29. The oral pharmaceutical composition of claim 1, wherein the SBTI is synthetic. 30. The oral pharmaceutical composition of claim 1, wherein the ratio of the anti-chymotrypsin activity to the anti-trypsin activity present in pharmaceutical composition is between 1.4:1 and 1.1:1 inclusive. 31. The oral pharmaceutical composition of claim 1, wherein the ratio of the anti-chymotrypsin activity to the anti-trypsin activity present in the pharmaceutical composition is between 1.35:1-1.2:1 inclusive. 32. The oral pharmaceutical composition of claim 1, wherein the BBI has been purified to at least 85% purity, as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 33. The oral pharmaceutical composition of claim 1, wherein the BBI has been purified to a protein content of greater than 95% by BCA (bicinchoninic acid) assay. 34. An oral pharmaceutical composition comprising an oil-based liquid formulation, wherein said oil-based liquid formulation comprises a therapeutic protein of up to 100 kilodalton, a chelator of divalent cations, and a Bowman-Birk Inhibitor (BBI), wherein the BBI has a ratio of anti-chymotrypsin activity to anti-trypsin activity present of between 1.5:1 and 1:1 inclusive, and wherein the BBI has been produced by a process comprising (a) subjecting soybean trypsin inhibitor (SBTI) to column chromatography under conditions in which fractions containing the SBTI's Bowman-Birk Inhibitor (BBI) activity elute separately from fractions containing the SBTI's Kunitz Trypsin Inhibitor (KTI) activity; (b) eluting and combining the fractions from (a) that contain the BBI activity; and (c) filtering the combined fractions from (b) that contain the BBI activity under conditions that reduce contaminants having a molecular weight of greater than 30 KDa to be less than 0.1% of the BBI preparation, thus producing a purified BBI product characterized in that: (i) contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the preparation; and (ii) 1 mg of the purified BBI product has an activity of about 40 BTEE units per mg of protein. 35. An oral pharmaceutical composition comprising an oil-based liquid formulation, wherein said oil-based liquid formulation comprises (a) a mixture of C.sub.8-C.sub.18 monoacylglycerols, diacylglycerols, and triacylglycerols; (b) PEG-32 monoesters and diesters of a mixture of C.sub.8-C.sub.18 fatty acids; (c) free PEG-32; (d) a therapeutic protein having a molecular weight of up to 100 kilodalton, (e) a chelator of divalent cations, (f) a purified BBI product characterized in that: (i) contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the BBI preparation; and (ii) 1 mg of the purified BBI product has an activity of about 40 BTEE units per mg of protein; (g) a purified KTI product characterized in that: (i) contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the KTI preparation; and (ii) 1 mg of the purified KTI product has an activity of about 10,000 BAEE units per mg of protein; wherein the weight/weight ratio of component (a) of said mixture to the sum of components (b) and (c) is between 10:90 and 30:70 inclusive; and wherein the ratio of anti-chymotrypsin activity to anti-trypsin activity in the pharmaceutical composition is between 1.5:1 and 1:1 inclusive. 36. The oral pharmaceutical composition of claim 35, wherein the oil is fish oil. 37. The oral pharmaceutical composition of claim 35, wherein the composition is water-free. 38. The oral pharmaceutical composition of claim 35, wherein the therapeutic protein is insulin or a GLP-1 analogue. 39. A method of preparing a medicament for orally administering a therapeutic protein to a subject, the method comprising coating the pharmaceutical composition of claim 1 with a coating that resists degradation in the stomach. 40. A method for making a pharmaceutical composition, the method comprising (a) providing a preparation of Bowman-Birk Inhibitor (BBI), wherein the BBI has been produced by a process comprising (i) subjecting soybean trypsin inhibitor (SBTI) to column chromatography under conditions in which fractions containing the SBTI's Bowman-Birk Inhibitor (BBI) activity elute separately from fractions containing the SBTI's Kunitz Trypsin Inhibitor (KTI) activity; (ii) eluting and combining the fractions from (i) that contain the BBI activity (iii) filtering the combined fractions from (ii) that contain the BBI activity under conditions that reduce contaminants having a molecular weight of greater than 30 KDa to be less than 0.1% of the BBI preparation, thus producing a purified BBI product characterized in that: contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the preparation; and 1 mg of the purified BBI product has an activity of about 40 BTEE units per mg of protein; and (b) mixing the preparation purified BBI product of part (iii) and a therapeutic protein of up to 100 kilodaltons into an oil-based liquid formulation; wherein the preparation of BBI that is mixed with the therapeutic protein is of a purity of at least 85% as measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE); and wherein the ratio of anti-chymotrypsin activity to anti-trypsin activity present in the pharmaceutical composition is between 1.5:1 and 1:1 inclusive. 41. The method of claim 40, wherein the BBI is isolated from a soybean product. 42. The method of claim 40, wherein the BBI is recombinant. 43. The method of claim 40, wherein the BBI is synthetic. 44. A method for making an oral pharmaceutical composition comprising (a) subjecting soybean trypsin inhibitor (SBTI) to column chromatography under conditions in which fractions containing the SBTI's Bowman-Birk Inhibitor (BBI) activity elute separately from fractions containing the SBTI's Kunitz Trypsin Inhibitor (KTI) activity; (b) eluting and combining the fractions from (a) that contain the BBI activity; (c) filtering the combined fractions from (a) that contain the BBI activity under conditions that reduce contaminants having a molecular weight of greater than 30 KDa to be less than 0.1% of the BBI preparation, thus producing a purified BBI product characterized in that: (i) contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the preparation; and (ii) 1 mg of the purified BBI product has an activity of about 40 BTEE units per mg of protein; (d) eluting and combining the fractions from (a) that contain the KTI activity and in which contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the preparation thus producing a purified KTI product characterized in that: (i) contaminants having a molecular weight greater than 30 KDa are less than 0.1% of the preparation; and (ii) 1 mg of the purified KTI product has an activity of about 10,000 BAEE units per mg of protein; (e) combining (i) an oil-based liquid formulation, (ii) a therapeutic protein having a molecular weight of up to 100 kilodalton, (iii) a chelator of divalent cations, (iv) the purified BBI product of part (b); and (v) the purified KTI product of part (c), such that the ratio of anti-chymotrypsin activity to anti-trypsin activity present in the pharmaceutical composition is between 1.5:1 and 1:1 inclusive. 45. The method of claim 44, wherein said oil-based liquid formulation further comprises (a) a mixture of C.sub.8-C.sub.18 monoacylglycerols, diacylglycerols, and triacylglycerols; (b) PEG-32 monoesters and diesters of a mixture of C.sub.8-C.sub.18 fatty acids; and (c) free PEG-32; and wherein the weight/weight ratio of component (a) of said mixture to the sum of components (b) and (c) is between 10:90 and 30:70 inclusive. 46. A method for orally administering a therapeutic protein to a subject, said method comprising the step of administering to a subject the oral pharmaceutical composition of claim 1, thereby orally administering a therapeutic protein to a subject. |
Details for Patent 10,342,764
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2032-02-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.